Atherosclerotic vascular events in a single large lupus cohort:: Prevalence and risk factors

被引:0
作者
Urowitz, Murray B. [1 ]
Ibanez, Dominique [1 ]
Gladman, Dafna D. [1 ]
机构
[1] Univ Toronto, Toronto Western Hosp, Lupus Clin, Ctr Prognosos Studies Rheumat Dis, Toronto, ON M5T 2S8, Canada
关键词
atherosclerotic vascular events; systemic lupus erythematosus; risk factors; coronary artery disease;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine prevalence and type of atherosclerotic vascular events (AVE) occurring after entry to the University of Toronto Lupus Clinic; and to compare risk factors in patients with systemic lupus erythematosus (SLE) with AVE to matched SLE controls without AVE. Methods. Patients with SLE attending the University of Toronto Lupus Clinic who did not have AVE prior to clinic entry were included. Patients have been followed at 2-6 months since 1970 according to a standard protocol. Cases with AVE were matched for sex, era at first clinic visit (1970s, 1980s, 1990s +), inception status, age at first visit, and duration of followup. Chi-square, Fisher's exact, paired T test, and McNemar test were used. Comparison of risk factors for the development of AVE was done using a stepwise conditional logistic regression model for matched pairs. Results. In a total cohort of 1087 SLE patients followed from 1970 until 2004, the prevalence of AVE was 10.9%, and in 561 inception patients it was 9.6%. In multivariate analyses, neuropsychiatric involvement was significantly associated with AVE in both the total and inception cohorts. Smoking was also associated with AVE in the inception cohort, whereas the number of coronary artery disease (CAD) risk factors and vasculitis were significant in the total cohort. Conclusion. AVE are major contributors to the clinical presentation of late-stage lupus. A combination of lupus related factors and classic CAD risk factors contributed to the development of AVE.
引用
收藏
页码:70 / 75
页数:6
相关论文
共 31 条
  • [1] ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
  • [2] ANTICARDIOLIPIN ANTIBODIES IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL AND LABORATORY CORRELATIONS
    ABUSHAKRA, M
    GLADMAN, DD
    UROWITZ, MB
    FAREWELL, V
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 99 (06) : 624 - 628
  • [3] Bruce IN, 1999, J RHEUMATOL, V26, P2137
  • [4] Risk factors for coronary heart disease in women with systemic lupus erythematosus -: The Toronto Risk Factor Study
    Bruce, IN
    Urowitz, MB
    Gladman, DD
    Ibañez, D
    Steiner, G
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3159 - 3167
  • [5] Premature atherosclerosis in systemic lupus erythematosus
    Bruce, IN
    Gladman, DD
    Urowitz, MB
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) : 257 - +
  • [6] Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
    Danesh, J
    Whincup, P
    Walker, M
    Lennon, L
    Thomson, A
    Appleby, P
    Gallimore, JR
    Pepys, MB
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7255): : 199 - 204
  • [7] Fodor JG, 2000, CAN MED ASSOC J, V162, P1441
  • [8] The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
    Gladman, D
    Ginzler, E
    Goldsmith, C
    Fortin, P
    Liang, M
    Urowitz, M
    Bacon, P
    Bombardieri, S
    Hanly, J
    Hay, E
    Isenberg, D
    Jones, J
    Kalunian, K
    Maddison, P
    Nived, O
    Petri, M
    Richter, M
    SanchezGuerrero, J
    Snaith, M
    Sturfelt, G
    Symmons, D
    Zoma, A
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (03): : 363 - 369
  • [9] Gladman DD, 2002, J RHEUMATOL, V29, P288
  • [10] Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5